Sam Brusco, Associate Editor08.18.22
Edwards Lifesciences’ PASCAL Precision transcatheter valve repair system has obtained CE mark approval to treat mitral and tricuspid regurgitation (MR and TR).
"Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," Bernard J. Zovighian, Edwards' corporate VP, transcatheter mitral and tricuspid therapies told the press. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR."
The system is used to treat patients with MR or TR via a single delivery system, and designed for precise navigation and implant delivery.
"The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to."
The system includes PASCAL and PASCAL Ace implants, which tout independent grasping, atraumatic clasp and closure, and the ability to elongate and navigate complex anatomy.
"Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," Bernard J. Zovighian, Edwards' corporate VP, transcatheter mitral and tricuspid therapies told the press. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR."
The system is used to treat patients with MR or TR via a single delivery system, and designed for precise navigation and implant delivery.
"The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to."
The system includes PASCAL and PASCAL Ace implants, which tout independent grasping, atraumatic clasp and closure, and the ability to elongate and navigate complex anatomy.